KIF20A抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-3: K562 cells, 293T cells, hela cells, Primary antibody: P08463(KIF20A Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08463(KIF20A Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08463(KIF20A Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

KIF20A (kinesin family member 20A), also known as MKLP2 (mitotic kinesin-like protein 2), is a member of the kinesin motor protein superfamily involved in intracellular transport and mitotic processes. It plays a critical role in cytokinesis, facilitating the separation of daughter cells during the final stages of cell division by regulating the formation and constriction of the midbody. KIF20A is predominantly expressed during the G2/M phase of the cell cycle and is essential for maintaining genomic stability. Dysregulation of KIF20A has been linked to various cancers, including hepatocellular carcinoma, pancreatic cancer, and breast cancer, where its overexpression correlates with tumor progression, metastasis, and poor prognosis.

Antibodies targeting KIF20A are valuable tools for studying its function, localization, and expression patterns in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate KIF20A's role in cell cycle regulation, cancer biology, and potential therapeutic targeting. Recent studies also explore KIF20A as a biomarker for cancer diagnosis and a candidate for immunotherapy, with efforts to develop inhibitory agents (e.g., small molecules or monoclonal antibodies) to disrupt its oncogenic activity. Its unique involvement in mitosis makes it a compelling subject for research in anti-mitotic drug development.